(Q95000126)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20578268%20AND%20SRC:MED&resulttype=core&format=json

21 May 2020

title

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20578268%20AND%20SRC:MED&resulttype=core&format=json

21 May 2020

1 reference

1 reference

1 reference

metabolic dysfunction–associated steatotic liver disease

1 reference

Giovanni Musso

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20578268%20AND%20SRC:MED&resulttype=core&format=json

21 May 2020

Roberto Gambino

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20578268%20AND%20SRC:MED&resulttype=core&format=json

21 May 2020

Maurizio Cassader

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20578268%20AND%20SRC:MED&resulttype=core&format=json

21 May 2020

Gianfranco Pagano

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20578268%20AND%20SRC:MED&resulttype=core&format=json

21 May 2020

publication date

1 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20578268%20AND%20SRC:MED&resulttype=core&format=json

21 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20578268%20AND%20SRC:MED&resulttype=core&format=json

21 May 2020

volume

52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20578268%20AND%20SRC:MED&resulttype=core&format=json

21 May 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20578268%20AND%20SRC:MED&resulttype=core&format=json

21 May 2020

page(s)

79-104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20578268%20AND%20SRC:MED&resulttype=core&format=json

Non-alcoholic fatty liver disease from pathogenesis to management: an update

21 May 2020

cites work

1 reference

7 January 2021

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

1 reference

7 January 2021

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

1 reference

7 January 2021

Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial

1 reference

7 January 2021

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

1 reference

7 January 2021

A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease

1 reference

7 January 2021

Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss.

1 reference

7 January 2021

Independent effects of physical activity in patients with nonalcoholic fatty liver disease

1 reference

7 January 2021

Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction

1 reference

7 January 2021

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

1 reference

7 January 2021

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

7 January 2021

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

7 January 2021

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

7 January 2021

Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis

1 reference

7 January 2021

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

1 reference

7 January 2021

The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis

1 reference

7 January 2021

Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation?

1 reference

7 January 2021

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

1 reference

7 January 2021

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design

1 reference

7 January 2021

Metformin in the treatment of patients with non-alcoholic steatohepatitis

1 reference

7 January 2021

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial

1 reference

7 January 2021

The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial

1 reference

7 January 2021

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

1 reference

7 January 2021

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease

1 reference

7 January 2021

Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease

1 reference

7 January 2021

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

1 reference

7 January 2021

Methods for assessing intrahepatic fat content and steatosis.

1 reference

7 January 2021

Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease

1 reference

7 January 2021

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia

1 reference

7 January 2021

Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy.

1 reference

7 January 2021

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis

1 reference

7 January 2021

Statins and liver toxicity: a meta-analysis

1 reference

7 January 2021

Statins and hepatic steatosis: perspectives from the Dallas Heart Study

1 reference

7 January 2021

An assessment of statin safety by hepatologists

1 reference

7 January 2021

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

1 reference

7 January 2021

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

1 reference

7 January 2021

Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study

1 reference

7 January 2021

Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study

1 reference

7 January 2021

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

1 reference

7 January 2021

Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis

1 reference

7 January 2021

A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid.

1 reference

7 January 2021

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

1 reference

7 January 2021

Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial

1 reference

7 January 2021

N-acetylcysteine in the treatment of non-alcoholic steatohepatitis

1 reference

7 January 2021

Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease.

1 reference

7 January 2021

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

1 reference

7 January 2021

A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH).

1 reference

7 January 2021

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

1 reference

7 January 2021

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial

1 reference

7 January 2021

L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial

1 reference

7 January 2021

Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis

1 reference

7 January 2021

Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease

1 reference

7 January 2021

Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty

1 reference

7 January 2021

Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease.

1 reference

7 January 2021

The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it

1 reference

7 January 2021

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.23623

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20578268%20AND%20SRC:MED&resulttype=core&format=json

21 May 2020

1 reference